Sign In
Buy SNGX
$0.483
-0.266 (-35.48%)
At Close: Jun 03, 2026
Soligenix and American Resources Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
09:00am, Friday, 16'th Aug 2024
ORLANDO, FL / ACCESSWIRE / August 16, 2024 / RedChip Companies will air interviews with Soligenix Inc. (Nasdaq:SNGX) and American Resources Corp. (Nasdaq:AREC) on the RedChip Small Stocks, Big Money�
Soligenix Announces Recent Accomplishments And Second Quarter 2024 Financial Results
07:30am, Friday, 09'th Aug 2024
PRINCETON, N.J. , Aug. 9, 2024 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to t
PRISM MarketView Features Q&A with Dr. Ellen Kim: Soligenix's HyBryte™— Lighting the Way Towards Commercial Success with Promising FLASH Study Results
Uncover Why This Pharma Stock Jumped 400% on Study Update
07:12am, Wednesday, 10'th Jul 2024
Soligenix Inc. NASDAQ: SNGX, a late-stage biopharmaceutical company, experienced an astonishing surge Tuesday. At the time of writing, the stock had soared nearly 400%.
5 Investors Betting Big on Soligenix (SNGX) Stock
02:37pm, Tuesday, 09'th Jul 2024
Shares of Soligenix (NASDAQ: SNGX ) are surging higher by over 300% following an update on the biopharmaceutical company's study of its HyBryte treatment. HyBryte focuses on patients with early-stage
Crude Oil Down 1%; Soligenix Shares Surge
12:11pm, Tuesday, 09'th Jul 2024
U.S. stocks traded mixed midway through trading, with the Nasdaq Composite gaining more than 50 points on Tuesday.
Nano-Cap Soligenix Stock Surges Over 200% On Tuesday, Here's Why
11:38am, Tuesday, 09'th Jul 2024
Soligenix Inc SNGX shares surged on Tuesday on a heavy volume of 23.6 million as per data from Benzinga Pro.
Why Is Soligenix (SNGX) Stock Up 296% Today?
10:04am, Tuesday, 09'th Jul 2024
Soligenix (NASDAQ: SNGX ) stock is rocketing higher on Tuesday following positive data from the late-stage biopharmaceutical company's extended HyBryte treatment. This data interim data comes from a 1
Expanded HyBryte™ Treatment Demonstrating Positive Outcomes in Early-Stage Cutaneous T-Cell Lymphoma
07:30am, Tuesday, 09'th Jul 2024
Study Supported by $2.6 Million FDA Orphan Products Development Grant PRINCETON, N.J. , July 9, 2024 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmace
HyBryte™ demonstrates more rapid and robust treatment response compared to Valchlor® during 12-week treatment course PRINCETON, N.J. , June 25, 2024 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (
A Comparison of Vaccine Technologies to be Presented at the ASM Microbe Conference
07:30am, Friday, 14'th Jun 2024
Advanced subunit vaccine technology, including SuVax™ and MarVax™, to be discussed alongside mRNA and viral vectored vaccine approaches PRINCETON, N.J., June 14, 2024 /PRNewswire/ -- Soligenix,
Soligenix and Sharps Technology Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
09:00am, Friday, 07'th Jun 2024
ORLANDO, FL / ACCESSWIRE / June 7, 2024 / RedChip Companies will air interviews with Soligenix, Inc. (Nasdaq:SNGX) and Sharps Technology Inc. (Nasdaq:STSS) on the RedChip Small Stocks, Big Money™ sh
Soligenix Announces Reverse Stock Split
07:30am, Friday, 31'st May 2024
Common Stock Will Begin Trading on Split-Adjusted Basis on June 6, 2024 PRINCETON, N.J., May 31, 2024 /PRNewswire/ -- Soligenix, Inc. (NASDAQ: SNGX) (Soligenix or the Company), a late-stage biopharmac
Soligenix Encourages Stockholders to Vote their Shares at the Annual Meeting
07:30am, Wednesday, 29'th May 2024
Most shareholders can vote by calling 1-833-782-7145 Only one day left to vote PRINCETON, N.J. , May 29, 2024 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage bi
Soligenix, Inc. Announces Adjournment of Annual Meeting, Information for Reconvened Annual Meeting
07:30am, Friday, 24'th May 2024
PRINCETON, N.J. , May 24, 2024 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to
